Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... “For Lilly, this is surely progress, but for many patients, at least in the near term, I ...

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed ... the company said it continued to make progress on building out its ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...